ResMed Inc. (RMD) on Decifer

Decifer ranks RMD number 92 of 269 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 10% a year, faster than 43 in 100 companies we measure.
• It keeps about 29 cents of every sales dollar as cash, safer than 92 in 100 companies we measure.
• It earns about 20% a year on the money put into the business, better than 85 in 100 companies we measure.
• It costs about 22 times its yearly profit; the middle of its industry is 34. Cheaper than 81 in 100 companies we measure, against their own industries.

The current read

The evidence on RMD lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full RMD research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.